Tracer Biotechnologies

Tracer Biotechnologies is pioneering a decentralized, vendor-agnostic platform to democratize access to ultrasensitive Minimal Residual Disease (MRD) monitoring in oncology. Their core innovation is a software layer that, combined with advanced AI, enables existing NGS and dPCR instruments to achieve single-part-per-million (ppm) sensitivity using generic, low-cost reagents, eliminating vendor lock-in. By decentralizing the testing workflow, Tracer addresses critical bottlenecks in cancer care logistics—such as tissue limitations, lengthy turnaround times, and centralized lab dependencies—empowering hospitals, CROs, and biopharma sites to conduct MRD testing locally. The company has announced a strategic partnership with AstraZeneca, signaling early validation of its platform for global clinical research.

A software and AI platform that transforms standard high-throughput NGS sequencers and dPCR instruments into ultrasensitive MRD detection systems using generic reagents. It features AI/ML signal extraction for single-ppm sensitivity, vendor-agnostic compatibility, and flexible cloud or on-premise deployment.

Tracer competes with established MRD liquid biopsy leaders like Natera (Signatera), Guardant Health (Guardant Reveal), and Adaptive Biotechnologies (clonoSEQ), which use proprietary wet-lab assays and centralized labs. Tracer's differentiation is its software-only, decentralized, and open platform that leverages customers' existing lab infrastructure, potentially offering greater flexibility and lower long-term costs.